Molecular Partners
Dec 21, 2018
Tetra, Shionogi sign deal; Amgen remunerates; Gilead’s fibrotic disease deal
Tetra, Shionogi sign USD 40 Million deal for Alzheimer’s disease and fragile X syndrome Tetra Discovery Partners is collaborating with Shionogi to progress its PDE4-targeting drug in Alzheimer’s disease and fragile X syndrome. Shionogi will give a USD 5 million upfront payment and USD 35 million in equ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
